Skip to main content
Premium Trial:

Request an Annual Quote

Allying with Syngene, Strand Genomics Eyes Cheminformatics Market

NEW YORK, June 3 (GenomeWeb Daily News) - Indian bioinformatics company Strand Genomics has entered the cheminformatics market through a newly disclosed partnership with Syngene in the field of synthetic chemistry and molecular biology, according to local media reports.

The newspaper Express Pharma Plus reported online that Vijay Chandru, chairman and CEO of Strand Genomics, said that Strand has started developing predictive models by "leveraging" its Avadis platform.


GenomeWeb News could not independantly verify the alliance by deadline.


Terms of the alliance call for Syngene to synthesize target-focused libraries developed by Strand, the paper said. The libraries would be "differentiated by the use of predictive models of drug-like properties of small molecules at the design stage," the paper reports.

Chandru is quoted as saying that the Avadis platform, when used in cheminformatics applications, "will be three to five times more remunerative than if it were used in research biology."

He told the paper that
Strandis "in talks with a number of players in the synthetic chemistry segment for potential partnership," according to the article, including Procitius Research of Sanmar group, GVK, and Sai Life Sciences.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.